Clinical Trials Browser

Phase 2 × Lymphoma, Mantle-Cell × Clinical Protocols × Clear all

NCT00261612 2006-10-18

Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

Phase 2 Unknown

Recurrence, Lymphoma, Mantle-Cell